New Adjuvant Treatments for Breast Cancer Prove Cost-Effective

New adjuvant treatments for breast cancer are cost-effective at improving survival, according to two new studies. Published in the August 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the two studies looked at the cost-effectiveness of different drugs for the management of adjuvant therapies for early breast cancer. In a Canadian economic study of estrogen receptor positive breast cancers, switching from tamoxifen to the oral steroidal aromatase inhibitor exemestane (trade name: Aromasin) extended disease free survival at a minimal cost per person. In another of study of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the addition of the anti-HER2 receptor monoclonal antibody, trastuzumab (trade name: Herceptin), is projected to improve life expectancy at a relatively low cost.